Amneal Pharmaceuticals, Inc. Class A Aktie News

Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Office...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie's NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis' AFINITOR DISPERZ...